Literature DB >> 23945392

Erlotinib response in an NSCLC patient with a novel compound G719D+L861R mutation in EGFR.

Eamon M Berge1, Dara L Aisner, Robert C Doebele.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23945392      PMCID： PMC4154819          DOI： 10.1097/JTO.0b013e31829ceb8d

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  5 in total

1.  A novel EGFR mutation in exon 18 with high sensitivity to EGFR TKI treatment with reduced dose.

Authors:  Erika P Brandão; Marcos Gustavo Pantarotto; Marcelo Cruz
Journal:  J Thorac Oncol       Date:  2012-11       Impact factor: 15.609

2.  Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer.

Authors:  Jenn-Yu Wu; Chong-Jen Yu; Yeun-Chung Chang; Chih-Hsin Yang; Jin-Yuan Shih; Pan-Chyr Yang
Journal:  Clin Cancer Res       Date:  2011-04-29       Impact factor: 12.531

3.  Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors.

Authors:  Susumu Kobayashi; Hannah M Canepa; Alexandra S Bailey; Sohei Nakayama; Norihiro Yamaguchi; Michael A Goldstein; Mark S Huberman; Daniel B Costa
Journal:  J Thorac Oncol       Date:  2013-01       Impact factor: 15.609

4.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

Authors:  Thomas J Lynch; Daphne W Bell; Raffaella Sordella; Sarada Gurubhagavatula; Ross A Okimoto; Brian W Brannigan; Patricia L Harris; Sara M Haserlat; Jeffrey G Supko; Frank G Haluska; David N Louis; David C Christiani; Jeff Settleman; Daniel A Haber
Journal:  N Engl J Med       Date:  2004-04-29       Impact factor: 91.245

Review 5.  Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer.

Authors:  Tetsuya Mitsudomi; Yasushi Yatabe
Journal:  FEBS J       Date:  2009-11-18       Impact factor: 5.542
  5 in total
  4 in total

1.  The study of homology between tumor progression genes and members of retroviridae as a tool to predict target-directed therapy failure.

Authors:  Janaina Fernandes
Journal:  Front Pharmacol       Date:  2015-05-01       Impact factor: 5.810

2.  Compound EGFR mutation is frequently detected with co-mutations of actionable genes and associated with poor clinical outcome in lung adenocarcinoma.

Authors:  Eun Young Kim; Eun Na Cho; Heae Surng Park; Ji Young Hong; Seri Lim; Jong Pil Youn; Seung Yong Hwang; Yoon Soo Chang
Journal:  Cancer Biol Ther       Date:  2016-01-19       Impact factor: 4.742

3.  Drug resistance missense mutations in cancer are subject to evolutionary constraints.

Authors:  Ran Friedman
Journal:  PLoS One       Date:  2013-12-20       Impact factor: 3.240

Review 4.  EGFR mutations as a prognostic and predictive marker in non-small-cell lung cancer.

Authors:  Shu Fang; Zhehai Wang
Journal:  Drug Des Devel Ther       Date:  2014-09-26       Impact factor: 4.162
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.